Eflornithine
- Generic Name
- Eflornithine
- Brand Names
- Vaniqa
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12F2N2O2
- CAS Number
- 70052-12-9
- Unique Ingredient Identifier
- ZQN1G5V6SR
- Background
Eflornithine is a prescription drug indicated in the treatment of facial hirsutism (excessive hair growth). Eflornithine hydrochloride cream for topical application is intended for use in women suffering from facial hirsutism and is sold by Allergan, Inc. under the brand name Vaniqa. Eflornithine for injection against sleeping sickness was manufactured by Sanofi Aventis and sold under the brand name Ornidyl in the USA. It is now discontinued. Eflornithine is on the World Health Organization's List of Essential Medicines.
- Indication
Eflornithine is indicated in the treatment of facial hirsutism (excessive hair growth).
- Associated Conditions
- Meningoencephalitic stage Trypanosoma brucei gambiense infection
- Associated Therapies
- Hair removal therapy
Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)
- Conditions
- Familial Adenomatous Polyposis
- Interventions
- First Posted Date
- 2011-12-01
- Last Posted Date
- 2021-06-08
- Lead Sponsor
- Cancer Prevention Pharmaceuticals, Inc.
- Target Recruit Count
- 171
- Registration Number
- NCT01483144
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
S0820, Adenoma and Second Primary Prevention Trial
- Conditions
- Colorectal Neoplasms
- Interventions
- First Posted Date
- 2011-05-09
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 354
- Registration Number
- NCT01349881
- Locations
- 🇺🇸
Alaska Women's Cancer Care, Anchorage, Alaska, United States
🇺🇸Alaska Regional Hospital, Anchorage, Alaska, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)
- Conditions
- Familial Adenomatous Polyposis
- Interventions
- First Posted Date
- 2010-11-23
- Last Posted Date
- 2015-04-24
- Lead Sponsor
- Cancer Prevention Pharmaceuticals, Inc.
- Registration Number
- NCT01245816
Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide
- First Posted Date
- 2010-01-29
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Giselle Sholler
- Target Recruit Count
- 21
- Registration Number
- NCT01059071
- Locations
- 🇺🇸
Connecticut Children's Hospital, Hartford, Connecticut, United States
🇺🇸Levine Children's Hospital, Charlotte, North Carolina, United States
🇺🇸UVM/FAHC, Burlington, Vermont, United States
Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer
- Conditions
- Adenomatous Polyp
- Interventions
- Other: PlaceboOther: Laboratory Biomarker AnalysisOther: Telephone-Based Intervention
- First Posted Date
- 2009-09-24
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 107
- Registration Number
- NCT00983580
- Locations
- 🇺🇸
University of Illinois College of Medicine - Chicago, Chicago, Illinois, United States
🇺🇸University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged Skin
- Conditions
- Other Benign Neoplasm of Skin, Unspecified
- Interventions
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- University of Arizona
- Target Recruit Count
- 184
- Registration Number
- NCT00601640
- Locations
- 🇺🇸
Virginia G. Piper Cancer Center at Scottsdale Healthcare - Shea, Tucson, Arizona, United States
🇺🇸Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona, United States
🇺🇸Veterans Affairs Medical Center - Tucson, Tucson, Arizona, United States
Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, Uganda
- Conditions
- Trypanosomiasis, African
- First Posted Date
- 2007-06-21
- Last Posted Date
- 2007-06-21
- Lead Sponsor
- Epicentre
- Target Recruit Count
- 31
- Registration Number
- NCT00489658
- Locations
- 🇺🇬
Yumbe District Hospital, Yumbe, Yumbe District, Uganda
Effect of 15% Eflornithine Hydrochloride Cream on African-American Males With Pseudofolliculitis Barbae
- Conditions
- Pseudofolliculitis Barbae
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2006-11-13
- Lead Sponsor
- Hordinsky, Maria K., MD
- Target Recruit Count
- 15
- Registration Number
- NCT00176995
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
Evaluation of Eflornithine on Facial and Forearm Skin
- Conditions
- Hirsutism
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2019-10-30
- Lead Sponsor
- Allergan
- Target Recruit Count
- 78
- Registration Number
- NCT00152048
Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis
- Conditions
- Trypanosomiasis, African
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2016-09-29
- Lead Sponsor
- Drugs for Neglected Diseases
- Target Recruit Count
- 280
- Registration Number
- NCT00146627
- Locations
- 🇨🇩
MSF-Belgium; PNLTHA, Epicentre, Isangi, Congo, The Democratic Republic of the
🇨🇩PNLTHA, STI, Epicentre, Mbuyi Maji, Congo, The Democratic Republic of the
🇨🇬MSF-Holland, Nkayi, RoC, Congo
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.